PFBT
ELVN icon

Parkside Financial Bank & Trust’s Enliven Therapeutics ELVN Stock Holding History

Parkside Financial Bank & Trust’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$588 Buy
+15
New +$416 ﹤0.01% 2528
2025
Q4 		– Sell
-25
Closed -$512 – 2718
2025
Q3 		$512 Hold
25
– – ﹤0.01% 2565
2025
Q2 		$502 Buy
+25
New +$473 ﹤0.01% 2552

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parkside Financial Bank & Trust's ELVN Position: Q1 2026 in Review

Parkside Financial Bank & Trust opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 15 shares worth $588. The stake represents ﹤0.01% of the portfolio and ranks #2528 among its holdings. This is a return to the name: Parkside Financial Bank & Trust previously reported a position in ELVN as recently as Q3 2025.

Parkside Financial Bank & Trust first reported a position in ELVN in Q2 2025 and has held it in 3 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Parkside Financial Bank & Trust held 15 shares of Enliven Therapeutics worth $588 as of Q1 2026.
  • Enliven Therapeutics was a new Parkside Financial Bank & Trust position in Q1 2026.
  • Enliven Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2528 holding.
  • Parkside Financial Bank & Trust first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.